Cellebrite DI (NASDAQ:CLBT - Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.01, RTT News reports. The company had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a positive return on equity of 25.28% and a negative net margin of 34.56%. The firm's revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 earnings per share. Cellebrite DI updated its Q3 2025 guidance to EPS and its FY 2025 guidance to EPS.
Cellebrite DI Stock Up 2.0%
NASDAQ CLBT traded up $0.31 during trading hours on Friday, hitting $15.60. 6,048,418 shares of the company were exchanged, compared to its average volume of 1,999,717. The company has a 50 day moving average of $14.98 and a two-hundred day moving average of $17.82. Cellebrite DI has a 52-week low of $13.10 and a 52-week high of $26.30. The firm has a market cap of $3.74 billion, a price-to-earnings ratio of -20.53, a PEG ratio of 3.09 and a beta of 1.27.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on CLBT shares. JPMorgan Chase & Co. lowered their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Needham & Company LLC decreased their price target on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday. Lake Street Capital cut their price objective on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday. Finally, Wall Street Zen downgraded Cellebrite DI from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Cellebrite DI presently has a consensus rating of "Moderate Buy" and an average target price of $21.00.
View Our Latest Analysis on Cellebrite DI
Institutional Investors Weigh In On Cellebrite DI
Large investors have recently bought and sold shares of the stock. First Trust Advisors LP purchased a new stake in Cellebrite DI during the 2nd quarter worth about $341,000. Alamea Verwaltungs GmbH increased its holdings in Cellebrite DI by 31.9% during the 2nd quarter. Alamea Verwaltungs GmbH now owns 22,277 shares of the company's stock worth $356,000 after purchasing an additional 5,383 shares during the period. SkyView Investment Advisors LLC increased its holdings in Cellebrite DI by 2.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company's stock worth $597,000 after purchasing an additional 970 shares during the period. Jane Street Group LLC purchased a new stake in Cellebrite DI during the 2nd quarter worth about $1,272,000. Finally, Tidal Investments LLC increased its holdings in Cellebrite DI by 60.9% during the 2nd quarter. Tidal Investments LLC now owns 96,157 shares of the company's stock worth $1,539,000 after purchasing an additional 36,402 shares during the period. Hedge funds and other institutional investors own 45.88% of the company's stock.
About Cellebrite DI
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access